Efficacy of PRaG therapy in microsatellite-stable metastatic colorectal cancer: a comparative analysis of PD-1/PD-L1 inhibitor-based combination therapies.

ABSTRACT:

Background

Most (95%) metastatic colorectal cancers (mCRCs) exhibit microsatellite stability (MSS) and proficiency in DNA mismatch repair (pMMR), leading to resistance to immunotherapy. To overcome this, the combination of programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors with other therapeutic strategies has been explored. This study evaluated the efficacy of PRaG therapy-a combination of PD-1 inhibitors, radiotherapy, and granulocyte‒macrophage colony-stimulating factor-in comparison with other combination therapies.

Methods

MSS/pMMR mCRC patients receiving PD-1/PD-L1 inhibitor combination therapy at the Second Affiliated Hospital of Soochow University were analyzed. Patients were grouped by therapy type, and SPSS 26.0 was used to ass

SUBMITTER: Yang J 

PROVIDER: S-EPMC12501090 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature